Sana Biotechnology (NASDAQ:SANA) Trading Down 5.3% – Here’s What Happened

Sana Biotechnology, Inc. (NASDAQ:SANA) shares dropped 5.3% on Friday . The stock traded as low as $3.48 and last traded at $3.4750. Approximately 978,713 shares were traded during trading, a decline of 69% from the average session volume of 3,114,402 shares. The stock had previously closed at $3.67.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SANA shares. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research report on Monday, May 11th. They issued a “buy” rating and a $16.00 price objective on the stock. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Finally, Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Trading Down 6.3%

The business’s 50 day simple moving average is $3.35 and its two-hundred day simple moving average is $3.45. The firm has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. As a group, equities research analysts anticipate that Sana Biotechnology, Inc. will post -0.56 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

Large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new stake in Sana Biotechnology during the second quarter valued at approximately $475,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Sana Biotechnology in the 2nd quarter worth $286,000. Ieq Capital LLC purchased a new stake in shares of Sana Biotechnology in the 2nd quarter worth $449,000. Callan Family Office LLC bought a new position in Sana Biotechnology in the 2nd quarter worth $43,000. Finally, LaSalle St. Investment Advisors LLC bought a new position in Sana Biotechnology in the 2nd quarter worth $77,000. 88.23% of the stock is currently owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.